Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 21st Preview)
-
In vivo CAR T expansion via M&A
Eli Lilly agreed to buy Kelonia Therapeutics in a deal worth up to $7 billion, adding an in vivo CAR T platform aimed at generating anti-BCMA T cells directly inside patients. Lilly will pay $3.25 billion upfront, with additional milestone payments tied to clinical, regulatory, and commercial outcomes. Kelonia’s lead asset, KLN-1010, is designed as a one-time intravenous therapy using Kelonia’s in vivo gene placement system to transform patients’ T cells into cancer-killing cells without ex vivo manufacturing. The company previously reported early clinical data in multiple myeloma, including MRD-negative responses in a small Phase I cohort. Lilly positioned the acquisition as a way to expand hematology reach beyond highly specialized ex vivo CAR T programs. The transaction is expected to close in the second half of 2026, subject to customary approvals and conditions.
-
Early interception strategy in smoldering myeloma with CAR T
Dana-Farber Cancer Institute investigators presented Phase 2 CAR-PRISM data using CAR T-cell therapy in high-risk smoldering multiple myeloma, a precursor stage aimed at preventing progression. In the trial update, all 20 treated patients achieved no detectable myeloma cells after therapy, generating a deeper-than-usual response profile. The study tests whether immune interception at an earlier disease stage can redefine treatment goals compared with current standard approaches. The findings were discussed alongside the context that the only approved therapy for high-risk smoldering myeloma is the antibody daratumumab, which typically requires longer treatment courses. If the durability holds, the results could strengthen the case for moving CAR T earlier in the myeloma timeline, though investigators and outside experts continue to emphasize the need for longer follow-up and defined endpoints.
-
Precision host-factor genomics in primary CD4 T cells for HIV
Gladstone Institutes and UCSF reported a genome-wide CRISPR map of human genes that promote or restrict HIV infection in primary CD4+ T cells. Published in Cell, the work provides a host–virus blueprint derived from the cell type HIV naturally targets, addressing limitations of prior studies using immortalized cell lines. The team overcame low infection efficiency in primary cells by boosting HIV infection rates to roughly 70% after optimization, enabling both CRISPR activation (CRISPRa) and knockout (CRISPRn) screens across near-complete gene sets. Perturbations revealed dependencies HIV exploits and antiviral defenses the virus suppresses. Researchers said the dataset can guide target selection for future host-directed therapies and improve understanding of why infection outcomes vary between individuals and contexts.
-
Oncology immunotherapy signal in NEOPRISM-CRC bowel cancer
UCL and UCLH reported follow-up results from the NEOPRISM-CRC trial testing a short course of immunotherapy before surgery for a subset of bowel cancer patients. The update highlighted zero relapses in the reported outcome set, suggesting a strong early disease-control signal for preoperative immunotherapy. The approach is built around giving immunotherapy prior to surgical intervention, with the intent to influence residual disease biology and post-surgery outcomes. The report adds to prior clinical discussion around neoadjuvant immunotherapy strategies and the search for response predictors. UCLH framed the findings as potentially practice-relevant for patients eligible for the trial regimen, while the broader field continues to await larger cohorts and longer-term confirmation.
-
Proteomics platform partnership for precision oncology workflows
Nomic Bio partnered with Broad Clinical Labs to integrate Nomic’s Nomic Omni 1000 immunoassay platform into BCL’s omics offerings. The collaboration is intended to combine broad protein immunoassay coverage with BCL’s genomic disease-risk models and precision oncology workflows, including use in clinical trials and multiomic studies. Nomic said its Omni 1000 uses nELISA technology to multiplex hundreds to thousands of immunoassays quickly without antibody cross-reactivity, and supports absolute quantification for more than 1,050 proteins. Initial development work is underway, with joint applications planned to be offered in early 2027. The deal reflects continued investment in scalable proteomics infrastructure aimed at making protein biomarkers more comparable to other modalities in translational research.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.